Novartis licenses Alteogen Hybrozyme technology for multiple subcutaneous products

The agreement gives Novartis options to secure exclusive rights to develop and commercialise multiple subcutaneous products using Alteogen's ALT-B4 Hybrozyme technology.

Alteogen has entered into an option and licence agreement with Novartis covering the development and commercialisation of subcutaneous formulations of multiple Novartis products using ALT-B4.

The deal further expands the global reach of Alteogen's Hybrozyme platform, which uses recombinant human hyaluronidase technology to enable medicines currently administered intravenously to be reformulated for subcutaneous delivery.

Field	Content
Alert Type	Deal
Companies	Alteogen; Novartis
Deal Type	Option and licence agreement
Asset or Company	ALT-B4 / Hybrozyme technology
Therapy Area(s)	Multiple therapeutic areas
Technology or Modality	Recombinant human hyaluronidase drug-delivery platform
Deal Value	Financial terms were not disclosed
Geography	Global
What Happened	Novartis obtained multiple options to secure exclusive rights to develop and commercialise subcutaneous formulations of multiple products using Alteogen's ALT-B4 Hybrozyme technology.
Why It Matters	The agreement extends adoption of Alteogen's drug-delivery platform by another major pharmaceutical company and could enable more convenient subcutaneous versions of existing biologic medicines.
Supporting Context	ALT-B4, or berahyaluronidase alfa, is a recombinant human hyaluronidase designed to facilitate conversion of intravenous biologic medicines into subcutaneous formulations.
Strategic Rationale	Novartis gains access to a platform that can support more convenient administration of multiple medicines while Alteogen expands the commercial reach of Hybrozyme.
Potential Impact	Successful development could reduce administration time and improve treatment convenience for products selected under the agreement.
Key Takeaway	Novartis has secured options to use Alteogen's ALT-B4 platform across multiple subcutaneous product programmes.
What to Watch	Which Novartis products are selected under the options and subsequent development of ALT-B4-enabled subcutaneous formulations.
Primary Source	Alteogen
Relevant Date	2 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com